Hypha Labs, Inc.
Hypha Labs, Inc. is a U.S.-based early-stage company that has shifted from cannabis/hemp testing services into developing the Hypha Micropearl bioreactor for functional mushroom cultivation. The company is currently focused on design, testing, and eventual commercialization of this device, while also seeking financing to support operations and product launch.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaThe Hypha Micropearl bioreactor and related hardware intended for mushroom cultivation.
Cartridges and other recurring components used with the accelerator device.
Design, testing, validation, and technical development work for the product platform.
Former cannabis and hemp testing laboratory services that were sold in 2024.
Asiakkaat
The company’s near-term customer base is expected to be limited and concentrated around early adopters of the Hypha Micropearl device and related cartridges. Management also expects initial testing feedback from mycologists and functional mushroom industry experts to shape the product before broader commercial launch. Historically, the business served cannabis and hemp customers, but that operating model was exited in 2024.
Buy the bioreactor to support controlled cultivation and improve growing consistency.
Purchase replacement cartridges and related components for repeat use of the device.
Provide technical feedback during product development and help validate performance.
Former customers of the sold laboratory business; no longer the core revenue base.
Strategia
The company’s strategy is to complete development and testing of the Hypha Micropearl bioreactor, then secure manufacturing and launch commercial sales. Near term, management is focused on raising capital, validating the product with experts, and preparing a launch target in late 2026. The business is also evaluating potential acquisition targets, but funding remains the key constraint.
Commercialization depends on proving the device works reliably before launch.
The company needs capital to fund operations, product development, and launch.
Commercial sales require a scalable supply chain outside the U.S.
Maantiede
Hypha Labs is headquartered in the United States and currently conducts limited product development and testing there. Management expects to source manufacturing outside the United States for commercial production, which introduces supply-chain and trade-policy exposure, including potential reliance on China-based manufacturers. The business is therefore U.S.-centered operationally today, but its future cost structure and execution risk will depend on offshore manufacturing arrangements.
Riskit
Hypha Labs is a going-concern-risk company with limited cash, negative working capital, and recurring losses, so financing risk is central to the investment case. Execution risk is also high because the company is still developing its product, depends on third-party suppliers and manufacturers, and may face delays in commercialization or supply disruptions. As a former testing-lab business, it also faces transition risk as it attempts to build a new revenue model from scratch.
- Going concern and financing shortfallVaikutus: KriittinenTodennäköisyys: Korkea
The company disclosed substantial doubt about its ability to continue without new capital.
Kohdistuu - Product development and commercialization delayVaikutus: KorkeaTodennäköisyys: Korkea
The bioreactor is still in design/testing, so launch timing and market acceptance are uncertain.
Kohdistuu: Revenue timing and operating losses
- Supplier concentration and component availabilityVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company may rely on limited or single suppliers for cartridges and other parts.
Kohdistuu: Manufacturing continuity and product quality
- Customer concentration in an early-stage launchVaikutus: KeskitasoTodennäköisyys: Korkea
Initial sales may depend on a small number of customers and repeat cartridge purchases.
Kohdistuu: Revenue volatility and order timing
- Foreign manufacturing and trade-policy exposureVaikutus: KeskitasoTodennäköisyys: Matala
Management may use manufacturers outside the U.S., including China, creating geopolitical risk.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätManagement disclosed substantial doubt about continued operations, which affects valuation and disclosure.
Vaikutus: May require heightened scrutiny of asset recoverability and financing assumptions
Equity awards are used for employee and nonemployee services and are measured at fair value.
Vaikutus: Can materially affect operating expenses and net loss
The company references ASC 820 for financial instruments and valuation hierarchy.
Vaikutus: Affects reported values for cash equivalents and any measured liabilities
Professional fees and development costs can vary sharply as the business transitions.
Vaikutus: Quarterly results may not be directly comparable
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Kyntra Bio, Inc
KYNB · Pharmaceutical Preparations
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Bicara Therapeutics Inc.
BCAX · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Papa Medical Inc.
Cigarettes
HOOKIPA Pharma Inc.
HOOK · Pharmaceutical Preparations
Päivitetty: 24.9.2026